Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
The human cannabinoid G-protein-coupled receptor 1 (CB1) is highly expressed in central nervous system. CB1-selective antagonists show therapeutic promise in a wide range of disorders, such as obesity-related metabolic disorders, dyslipidemia, drug abuse, and type 2 diabetes. Rimonabant (SR141716A), MJ08, and MJ15 are selective CB1 antagonists with selectivity >1,000-folds over CB2 despite 42% sequence identity between CB1 and CB2. The integration of homology modeling, automated molecular docking, and molecular dynamics simulation were used to investigate the binding modes of these selective inverse agonists/antagonists with CB1 and CB2 and their selectivity. Our analyses showed that the hydrophobic interactions between ligands and hydrophobic pockets of CB1 account for the main binding affinity. In addition, instead of interacting with ligands directly as previously reported, the Lys1923.28 in CB1 was engaged in indirect interactions with ligands to keep inactive-state CB1 stable by forming the salt bridge with Asp1762.63 . Lastly, our analyses indicated that the selectivity of these antagonists came from the difference in geometry shapes of binding pockets of CB1 and CB2. The present study could guide future experimental works on these receptors and has the guiding significance for the design of functionally selective drugs targeting CB1 or CB2 receptors.
['Liu|Cheng|C|', 'Yuan|Congmin|C|', 'Wu|Pinwen|P|', 'Zhu|Chen|C|', 'Fang|Hao|H|', 'Wang|Lili|L|', 'Fu|Wei|W|0000-0002-2335-8908']
D001665:Binding Sites D054314:Drug Inverse Agonism D006801:Humans D006860:Hydrogen Bonding D007700:Kinetics D062105:Molecular Docking Simulation D056004:Molecular Dynamics Simulation D017434:Protein Structure, Tertiary D043884:Receptor, Cannabinoid, CB1 D043885:Receptor, Cannabinoid, CB2 D000077285:Rimonabant
rimonabant cannabinoid receptor molecular modeling